In terms of both patient numbers and clinical effect, infections associated with methicillin-resistant Staphylococcus aureus (MRSA) present a significant challenge to clinicians. Serious S aureus infections are associated with high morbidity and mortality, with the acquisition of methicillin resistance further limiting therapeutic options. In recent years, so-called community-acquired MRSA strains (USA300 strain) have proven highly virulent and particularly difficult to control.1 As such, novel approaches to MRSA prevention remain a priority.
Malani PN. National Burden of Invasive Methicillin-Resistant Staphylococcus aureus Infection. JAMA. 2014;311(14):1438-1439. doi:10.1001/jama.2014.1666